Ayyubova G, Madhu L
Mol Neurobiol. 2025; .
PMID: 39951189
DOI: 10.1007/s12035-025-04758-z.
Long C, Fritts A, Broadway J, Brawman-Mintzer O, Mintzer J
J Clin Med. 2025; 14(2.
PMID: 39860337
PMC: 11766252.
DOI: 10.3390/jcm14020331.
Wang Q, Zhu B, Lei P
Zool Res. 2024; 45(6):1385-1407.
PMID: 39572020
PMC: 11668949.
DOI: 10.24272/j.issn.2095-8137.2024.274.
Beura S, Panigrahi A, Yadav P, Kulkarni P, Lakhanpal V, Singh B
Mol Neurobiol. 2024; 62(4):4802-4836.
PMID: 39482419
DOI: 10.1007/s12035-024-04589-4.
Salim Abed H, Oghenemaro E, Kubaev A, Jeddoa Z, S R, Sharma S
Cell Biochem Biophys. 2024; .
PMID: 39424765
DOI: 10.1007/s12013-024-01585-2.
dipeptides activate the NLRP3 inflammasome.
Rivers-Auty J, Hoyle C, Pointer A, Lawrence C, Pickering-Brown S, Brough D
Brain Commun. 2024; 6(5):fcae282.
PMID: 39229486
PMC: 11369816.
DOI: 10.1093/braincomms/fcae282.
Targeting Microglia in Alzheimer's Disease: Pathogenesis and Potential Therapeutic Strategies.
Sun Z, Zhang X, So K, Jiang W, Chiu K
Biomolecules. 2024; 14(7).
PMID: 39062547
PMC: 11274940.
DOI: 10.3390/biom14070833.
Research Progress on Micro(nano)plastic-Induced Programmed Cell Death Associated with Disease Risks.
Liu H, Li H, Chen T, Yu F, Lin Q, Zhao H
Toxics. 2024; 12(7).
PMID: 39058145
PMC: 11281249.
DOI: 10.3390/toxics12070493.
Targeting NLRP3 Inflammasomes: A Trojan Horse Strategy for Intervention in Neurological Disorders.
Bayat Tork M, Fotouhi S, Roozi P, Negah S
Mol Neurobiol. 2024; 62(2):1840-1881.
PMID: 39042218
DOI: 10.1007/s12035-024-04359-2.
From inflammatory signaling to neuronal damage: Exploring NLR inflammasomes in ageing neurological disorders.
Zhang J, Xie D, Jiao D, Zhou S, Liu S, Ju Z
Heliyon. 2024; 10(12):e32688.
PMID: 38975145
PMC: 11226848.
DOI: 10.1016/j.heliyon.2024.e32688.
Antiseizure properties of fenamate NSAIDs determined in mature human stem-cell derived neuroglial circuits.
Salmanzadeh H, Halliwell R
Front Pharmacol. 2024; 15:1385523.
PMID: 38828453
PMC: 11141243.
DOI: 10.3389/fphar.2024.1385523.
New Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation.
Kodi T, Sankhe R, Gopinathan A, Nandakumar K, Kishore A
J Neuroimmune Pharmacol. 2024; 19(1):7.
PMID: 38421496
PMC: 10904444.
DOI: 10.1007/s11481-024-10101-5.
Inflammasome signaling is dispensable for ß-amyloid-induced neuropathology in preclinical models of Alzheimer's disease.
Srinivasan S, Kancheva D, De Ren S, Saito T, Jans M, Boone F
Front Immunol. 2024; 15:1323409.
PMID: 38352874
PMC: 10863058.
DOI: 10.3389/fimmu.2024.1323409.
The elementary reactions for incorporation into crystals.
Chakrabarti R, Verma L, Hadjiev V, Palmer J, Vekilov P
Proc Natl Acad Sci U S A. 2024; 121(7):e2320201121.
PMID: 38315836
PMC: 10873555.
DOI: 10.1073/pnas.2320201121.
Mefenamic Acid Loaded and TPGS Stabilized Mucoadhesive Nanoemulsion for the Treatment of Alzheimer's Disease: Development, Optimization, and Brain-Targeted Delivery via Olfactory Pathway.
Dogra A, Narang R, Kaur T, Narang J
AAPS PharmSciTech. 2024; 25(1):16.
PMID: 38200387
DOI: 10.1208/s12249-023-02727-0.
Potential Impact of Bioactive Compounds as NLRP3 Inflammasome Inhibitors: An Update.
Singh S, Sharma S, Sharma H
Curr Pharm Biotechnol. 2024; 25(13):1719-1746.
PMID: 38173061
DOI: 10.2174/0113892010276859231125165251.
Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases.
Wang L, Zhu Y, Zhang L, Guo L, Wang X, Pan Z
Cell Death Dis. 2023; 14(12):851.
PMID: 38129399
PMC: 10739961.
DOI: 10.1038/s41419-023-06370-2.
Physiological roles of chloride ions in bodily and cellular functions.
Marunaka Y
J Physiol Sci. 2023; 73(1):31.
PMID: 37968609
PMC: 10717538.
DOI: 10.1186/s12576-023-00889-x.
NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors.
Xu Y, Yang Y, Chen X, Jiang D, Zhang F, Guo Y
Transl Neurodegener. 2023; 12(1):49.
PMID: 37915104
PMC: 10621314.
DOI: 10.1186/s40035-023-00381-x.
Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond.
Garmendia J, De Sanctis C, Das V, Annadurai N, Hajduch M, De Sanctis J
Curr Neuropharmacol. 2023; 22(6):1080-1109.
PMID: 37898823
PMC: 10964103.
DOI: 10.2174/1570159X22666231017141636.